iiinova — where your digital self keeps evolving

Talha Badar @talhabadarmd.bsky.social · 04/10/2026

Should we transplant #TP53-mutated MDS? Outcomes are poor, but poor ≠ futile. Selected patients can achieve durable survival after alloHCT. TP53 should trigger refinement, not automatic exclusion. Select carefully. Transplant deliberately. Prevent relapse aggressively.👇🏽

000

Talha Badar @talhabadarmd.bsky.social · 28/09/2026

🧠 CNS prophylaxis remains essential in ALL, especially as therapy becomes chemo-attenuated or chemo-free. Blinatumomab/inotuzumab do not replace CNS-directed therapy. Modern regimens often use 12–15 IT treatments, tailored to regimen and risk. #ALL #Leukemia #Hematology

020

Talha Badar @talhabadarmd.bsky.social · 21/09/2026

#weekend_review #mdssm HIGHER-RISK #MDS: A DECADE OF CLINICAL TRIALS The last decade in HR-MDS has taught us a humbling lesson Promising biology ≠ successful phase III trial. Higher response rate ≠ longer survival. why so many failed, and where we go next. 👇

021

Talha Badar @talhabadarmd.bsky.social · 08/08/2026

Exciting #DELPHINUS results: Dara + chemo achieved 83% ORR, with 75% proceeding to allo-HSCT and 24-month OS of 41% in R/R T-ALL. As EA9213 co-chair, excited to see whether Dara can eradicate MRD and deepen remission in T-ALL. #TcellALL #Leusm doi.org/10.1182/bloo...

doi.org

Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study

Key PointsDaratumumab plus chemotherapy may effectively bridge children and young adults with relapsed/refractory T-cell ALL/LL to HSCT.No new safety conce

010

Talha Badar @talhabadarmd.bsky.social · 08/08/2026

@bloodjournal.bsky.social study evaluated using leukemia cell lines Ziftomenib ⬇️ MEIS1/HOXA signaling, induced differentiation, and caused leukemia regression in NPM1/KMT2Ar CRISPR-engineered MEN1-mt models showed activity > T349M & G331R—but resistance> M327I/G331D. #AML doi.org/10.1182/bloo...

doi.org

Discovery and preclinical activity of the menin-KMT2A inhibitor ziftomenib in acute leukemia models

Key PointsZiftomenib shows pronounced preclinical activity in the menin-KMT2A–dependent leukemia models, including patient-derived xenografts.Ziftomenib de

030

Reposted by Talha Badar

Kate Sears @katesears.bsky.social · 21/07/2026

Newly Diagnosed Philadelphia Chromosome–Positive ALL: Frontline TKI Selection, Early Blinatumomab, MRD, and Allo-HCT Decision-Making algorithm from @talhabadarmd.bsky.social: myopenmedicine.com/algorithms/n...

myopenmedicine.com

Newly Diagnosed Philadelphia Chromosome–Positive ALL:Frontline TKI Selection, Early Blinatumomab, MRD, and Allo-HCT Decision-Making

022

Talha Badar @talhabadarmd.bsky.social · 18/07/2026

On call and need a quick refresher on newly diagnosed #Ph+ #ALL? I created a practical, evidence-based clinical algorithm covering: • Frontline TKI selection • Early blinatumomab integration • MRD-guided decision making • When to consider allo-HCT myopenmedicine.com/algorithms/n...

myopenmedicine.com

Newly Diagnosed Philadelphia Chromosome–Positive ALL:Frontline TKI Selection, Early Blinatumomab, MRD, and Allo-HCT Decision-Making

020

Talha Badar @talhabadarmd.bsky.social · 17/07/2026

@VuMedi talk on our COMMAND Consortium study in Ph+ ALL. Early CMR (3 months) identifies patients with excellent outcomes. AlloHCT reduced relapse but did not improve OS, supporting a more individualized, MRD-guided transplant strategy. #Leukemia #PhALL #HemOnc www.vumedi.com/video/predic...

vumedi.com

Predictors of Complete Molecular Response and AlloHSCT Outcomes in Philadelphia Chromosome–Positive ALL: The COMMAND Study

A video from Talha Badar, posted on Jul 14, 2026.

020

Reposted by Talha Badar

Anand Patel @anand-88-patel.bsky.social · 12/01/2026

check out this paper in @bloodjournals.hematology.org led by @talhabadarmd.bsky.social on PPM1D in CHIP/CCUS! Glad to contribute to this effort pubmed.ncbi.nlm.nih.gov/41499760/

022

Reposted by Talha Badar

Anand Patel @anand-88-patel.bsky.social · 09/04/2026

excited to be a part of this effort looking at the impact of CMR on survival outcomes in Ph+ ALL led by @talhabadarmd.bsky.social! www.tandfonline.com/doi/full/10....

021

Reposted by Talha Badar

Talha Badar @talhabadarmd.bsky.social · 26/10/2025

👇🏽 Trial finding that led to approval: Menin inhibitor revumenib showed promising efficacy in R/R NPM1-mutated AML — CR + CRh = 23%, ORR ≈ 47%, median DOR ~ 4.7 mo, manageable QTc prolongation. 📈 Led to FDA approval (2025) for R/R NPM1m AML. #AML #Revumenib #MeninInhibitor doi.org/10.1182/blood.…

001

Reposted by Talha Badar

Talha Badar @talhabadarmd.bsky.social · 29/10/2025

AML-defining cytogenetic and molecular abnormalities (regardless of blast count)between the WHO 5th Edition (2022) and the International Consensus Classification (ICC 2022). #leusm #MedTwitter #hemonctrainees #when_on_service 👇🏽

001

Talha Badar @talhabadarmd.bsky.social · 29/10/2025

001

Talha Badar @talhabadarmd.bsky.social · 29/10/2025

Olutasidenib alone or combined with azacitidine in pts with IDH1m MDS ashpublications.org/bloodadvances/… 👉🏾 PI/II data, Oluta show ORR (59%), CR ~27%, mDOR 14.6 mo & CR duration 20.5 mo; mOS 27.2 mo (n≈19) 👉🏾 cross-trial comparison; Ivo in MDS (image 2) ORR was 83% CR 39%, &mDOR NR, mOS 36 mo #mds

ashpublications.org

000

Talha Badar @talhabadarmd.bsky.social · 29/10/2025

Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML ashpublications.org/bloodadvances/… #Agile_study:mOS 24 mo. #cross-trial comparison; VIALE-A trial mOS IDH2-m AML ( 27.5 vs 13 mo) & IDH1-m AML (median 10.2 vs 2.2 mo) #leusm #AML

000

Talha Badar @talhabadarmd.bsky.social · 26/10/2025

001